Ichor at $74 Is Testing the Bull Case: Demand Is Real, but the Stock Is Pricing Perfection

Fair value is still negative even as the stock acts like the turnaround is already proven

This is the valuation test.

At roughly $74.42 current market price, Ichor is trading as if investors already believe the turnaround is working. The income statement has not earned that confidence yet. A fair-value model that flags negative EPS still points to -$7.60. That gap is extreme, but it makes the real point: the market is no longer valuing current earnings power. It is pricing a future recovery that is still speculative in the numbers.

The earlier rerating already baked in some optimism

That helps explain why the move can still feel fragile. When the stock was near $47.59 in February, it already carried a forward P/E of 38.31. Optimism was not starting from zero.

The latest quarter does show progress: Q1 2026 revenue of $256.1 million and a basic EPS loss of $0.07. But that is not the same as earnings power. Ichor still carries a trailing 12-month basic EPS loss of $1.47.

So the debate is straightforward. Bulls think the revenue base can support cleaner margins soon. Bears think investors are celebrating early recovery signs before profitability is actually proven. With fair value still negative, ICHR at $74 is a vote on management's future, not a reading of today's income statement.

Why the bull case still has room to exist

The market can forgive current losses if demand looks real and durable. On that point, bulls still have material ground to stand on.

Demand is the core reason the story has not broken

Management said unconstrained Q2 2026 demand exceeded $300 million, and Ichor still expects sales to rise each quarter in 2026. In this part of the supply chain, that matters because demand only becomes valuable if it turns into shipments, installed base, and repeat subsystem content. The fact that demand is strongest in etch and deposition also helps: those are areas where Ichor already has engineering footholds.

That is also why the stock can stay interesting despite the losses. Ichor builds gas and chemical delivery systems for major equipment platforms, and those relationships matter in semiconductor supply chains. Once a supplier is inside a tool architecture, customers are less likely to swap partners on a whim.

Mix, not just volume, is the upside lever

The bigger prize is not only more units. It is better economics per system. Ichor's stated goal is to lift Ichor-branded content from 25% at the end of 2025 to 35% by the end of 2026. If that happens, revenue can grow with a better mix of proprietary content rather than more low-margin pass-through work. That is the core margin-expansion mechanism behind the bull case.

What bulls still need to see

Bulls do not need perfection. They need proof across three areas:

• demand converts into revenue quarter after quarter
• branded content and proprietary mix actually improve
• execution in Mexico and Malaysia does not push margins back

So far, that case is alive, even if it is still unproven.

Why a real recovery can still be a bad stock entry

At roughly $74.42, ICHR is no longer being judged on today's earnings power. The income statement still argues that the recovery is unfinished: 2025 net sales of $947.7 million produced gross profit of $87.8 million, an operating loss of $(39.3) million, and a net loss of $(52.8) million. Revenue growth has not yet translated into durable profitability.

The business is still structurally weak

That weakness is broader than one year. Ichor has posted three straight years of net losses, with gross margins around 12.6%, negative free cash flow, and return on invested capital of -8.38%. That does not kill the turnaround story. It does mean timing matters. If margin improvement arrives later than investors expect, the stock can retrace even if the business gets better.

Once the market latches onto unconstrained Q2 2026 demand exceeded $300 million, it becomes easier to treat rising demand as proof that profits will follow. For now, that bridge is still under construction.

Customer concentration can make that mismatch more expensive. Two customers accounted for 76% of 2025 sales. That setup can amplify both outcomes: strong pull-through from major customers can support further upside, while shipment delays, qualification drag, or mix slippage can trigger an equally fast re-rating lower.

That is why a real recovery can still be a bad stock entry at this price: investors are paying for the timing of profitability before it shows up in the numbers.